Anita Bellail
Discovery and Development of a Molecular Glue Co-Degrader Targeting KRAS Mutant and CRAF via a Novel E3 Ligase. HB Therapeutics, Inc.
Seminars
Thursday 18th September 2025
Discovery of a Novel Molecular Glue Degrader Engaging a New E3 Ligase to Target KRAS Mutants & C-RAF
9:00 am
- Discovery of a novel small-molecule glue degrader with selectivity for KRAS mutants over KRAS WT
- Identification of a new E3 ligase pathway independent of the Cullin-RING system
- Dual degradation of mutant KRAS in complex with C-RAF
